JP2018505658A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018505658A5 JP2018505658A5 JP2017530266A JP2017530266A JP2018505658A5 JP 2018505658 A5 JP2018505658 A5 JP 2018505658A5 JP 2017530266 A JP2017530266 A JP 2017530266A JP 2017530266 A JP2017530266 A JP 2017530266A JP 2018505658 A5 JP2018505658 A5 JP 2018505658A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- tumor
- rna
- score
- genes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims 41
- 206010028980 Neoplasm Diseases 0.000 claims 37
- 230000004547 gene signature Effects 0.000 claims 29
- 239000000523 sample Substances 0.000 claims 25
- 238000000034 method Methods 0.000 claims 21
- 239000000090 biomarker Substances 0.000 claims 18
- 230000014509 gene expression Effects 0.000 claims 17
- 230000004044 response Effects 0.000 claims 15
- 229940124060 PD-1 antagonist Drugs 0.000 claims 10
- 230000006023 anti-tumor response Effects 0.000 claims 10
- 229960002621 pembrolizumab Drugs 0.000 claims 5
- 230000002596 correlated effect Effects 0.000 claims 4
- 230000002601 intratumoral effect Effects 0.000 claims 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 238000009396 hybridization Methods 0.000 claims 3
- 206010061424 Anal cancer Diseases 0.000 claims 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 201000011165 anus cancer Diseases 0.000 claims 2
- 201000009036 biliary tract cancer Diseases 0.000 claims 2
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 2
- 230000000875 corresponding effect Effects 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000003733 ovarian melanoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 229960000106 biosimilars Drugs 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000004590 computer program Methods 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
- 238000010998 test method Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462089538P | 2014-12-09 | 2014-12-09 | |
| US62/089,538 | 2014-12-09 | ||
| US201562160284P | 2015-05-12 | 2015-05-12 | |
| US62/160,284 | 2015-05-12 | ||
| PCT/US2015/064445 WO2016094377A1 (en) | 2014-12-09 | 2015-12-08 | System and methods for deriving gene signature biomarkers of response to pd-1 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018505658A JP2018505658A (ja) | 2018-03-01 |
| JP2018505658A5 true JP2018505658A5 (enExample) | 2018-12-27 |
Family
ID=56108044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017530266A Pending JP2018505658A (ja) | 2014-12-09 | 2015-12-08 | Ｐｄ−１アンタゴニストに対する応答の遺伝子シグネチャーバイオマーカーを得るための系および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11377693B2 (enExample) |
| EP (1) | EP3230498B1 (enExample) |
| JP (1) | JP2018505658A (enExample) |
| KR (1) | KR20170086661A (enExample) |
| CN (1) | CN107109700A (enExample) |
| AU (2) | AU2015360736A1 (enExample) |
| BR (1) | BR112017012222A2 (enExample) |
| CA (1) | CA2968406A1 (enExample) |
| MX (1) | MX2017007535A (enExample) |
| RU (1) | RU2017123117A (enExample) |
| WO (1) | WO2016094377A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2529747T (pt) | 2005-12-02 | 2018-05-09 | Icahn School Med Mount Sinai | Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações |
| US8354509B2 (en) | 2007-06-18 | 2013-01-15 | Msd Oss B.V. | Antibodies to human programmed death receptor PD-1 |
| NZ711946A (en) | 2013-03-14 | 2020-05-29 | Icahn School Med Mount Sinai | Newcastle disease viruses and uses thereof |
| MX370449B (es) | 2013-12-12 | 2019-12-13 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este. |
| WO2015127501A1 (en) | 2014-02-27 | 2015-09-03 | Viralytics Limited | Combination method for treatment of cancer |
| JP6767096B2 (ja) * | 2014-12-11 | 2020-10-14 | リティックス バイオファーマ エイエス | 免疫チェックポイント阻害剤の組み合わせ |
| EP3839510A3 (en) | 2015-04-17 | 2021-08-25 | Merck Sharp & Dohme Corp. | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists |
| WO2017177230A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| US10438699B2 (en) * | 2016-05-10 | 2019-10-08 | Macau University Of Science And Technology | Method and system for determining an association of biological features with a medical condition |
| WO2018067937A1 (en) * | 2016-10-07 | 2018-04-12 | Omniseq, Inc. | Methods and systems for determining personalized therapies |
| US20190376146A1 (en) * | 2016-11-24 | 2019-12-12 | Daiichi Sankyo Company, Limited | Method for predicting sensitivity of cancer to treatment with pd-1 immune checkpoint inhibitor |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| WO2019200223A1 (en) * | 2018-04-13 | 2019-10-17 | X4 Pharmaceuticals, Inc. | Cancer serum biomarkers and methods of use thereof |
| WO2019213478A1 (en) | 2018-05-04 | 2019-11-07 | Nanostring Technologies, Inc. | Gene expression assay for measurement of dna mismatch repair deficiency |
| WO2019222075A1 (en) | 2018-05-14 | 2019-11-21 | Merck Sharp And Dohme Corp. | Biomarkers for a combination therapy comprising lenvatinib and a pd-1 antagonist |
| US20210363590A1 (en) * | 2018-05-21 | 2021-11-25 | Nanostring Technologies, Inc. | Molecular gene signatures and methods of using same |
| WO2020005068A2 (en) * | 2018-06-29 | 2020-01-02 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Gene signatures and method for predicting response to pd-1 antagonists and ctla-4 antagonists, and combination thereof |
| EP3837277A4 (en) | 2018-08-17 | 2022-05-11 | Icahn School of Medicine at Mount Sinai | RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION |
| EP3891185A2 (en) * | 2018-12-05 | 2021-10-13 | F. Hoffmann-La Roche AG | Diagnostic methods and compositions for cancer immunotherapy |
| WO2020243568A1 (en) * | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
| WO2021030156A1 (en) * | 2019-08-09 | 2021-02-18 | The Regents Of The University Of California | Compositions and methods for diagnosis and treatment of bladder cancer |
| WO2021061749A1 (en) | 2019-09-24 | 2021-04-01 | Mirati Therapeutics, Inc. | Combination therapies |
| EP4055054A4 (en) * | 2019-11-04 | 2024-06-05 | Merck Sharp & Dohme LLC | ANGIOGENESIS- AND MDSC-GENE EXPRESSION-BASED TUMOR MARKER OF TUMOR RESPONSE TO PD-1 ANTAGONISTS |
| EP4069869A1 (en) * | 2019-12-04 | 2022-10-12 | Servicio Andaluz De Salud | Method to predict the response to cancer treatment with anti-pd1 immunotherapy |
| CN111088360A (zh) * | 2020-01-17 | 2020-05-01 | 暨南大学 | Pd1-ctla4和/或pdl2-ctla4在制备预测aml预后试剂盒中的应用 |
| WO2021183650A1 (en) | 2020-03-10 | 2021-09-16 | X4 Pharmaceuticals, Inc. | Methods for treating neutropenia |
| WO2022074648A1 (en) * | 2020-10-05 | 2022-04-14 | 4C Biomed Limited | Marker for response to pd-1/pd-l1 immunotherapy |
| WO2022135402A1 (zh) * | 2020-12-24 | 2022-06-30 | 信达生物制药(苏州)有限公司 | Pd-l1和/或mhc-2生物标记物在预测肺癌患者治疗疗效中的用途 |
| US20240336971A1 (en) * | 2021-07-22 | 2024-10-10 | Asylia Diagnostics Bv | Biomarkers for Therapy Response After Immunotherapy |
| IL314037A (en) | 2022-01-03 | 2024-09-01 | Checkmate Pharmaceuticals Inc | Transcriptional biomarkers for response to innate immune activators |
| WO2023244632A1 (en) * | 2022-06-17 | 2023-12-21 | Merck Sharp & Dohme Llc | Genome wide tumor derived gene expression based signatures associated with poor prognosis for melanoma patients with early stage disease |
| WO2024083867A1 (en) | 2022-10-17 | 2024-04-25 | Ultimovacs Asa | Biomarker |
| WO2024112609A1 (en) * | 2022-11-21 | 2024-05-30 | Merck Sharp & Dohme Llc | Genome wide tumor derived gene expression based signatures associated with poor prognosis for melanoma patients with early stage disease |
| WO2024225488A1 (ja) * | 2023-04-27 | 2024-10-31 | 株式会社リプロセル | 抗ｐｄ－１抗体療法に応答性である候補がん患者を同定する方法 |
| WO2025034883A1 (en) | 2023-08-08 | 2025-02-13 | Quanta Therapeutics, Inc. | Combination therapies with kras modulators |
| WO2025106905A1 (en) | 2023-11-17 | 2025-05-22 | Quanta Therapeutics, Inc. | Combination therapies with a kras modulator and an immunomodulator inhibitor |
| WO2025136845A1 (en) * | 2023-12-19 | 2025-06-26 | Merck Sharp & Dohme Llc | Methods of treating a patient with a pd-1 antagonist |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
| US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| GB8822228D0 (en) | 1988-09-21 | 1988-10-26 | Southern E M | Support-bound oligonucleotides |
| US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
| US5242974A (en) | 1991-11-22 | 1993-09-07 | Affymax Technologies N.V. | Polymer reversal on solid surfaces |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5547839A (en) | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5424186A (en) | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
| DE3924454A1 (de) | 1989-07-24 | 1991-02-07 | Cornelis P Prof Dr Hollenberg | Die anwendung von dna und dna-technologie fuer die konstruktion von netzwerken zur verwendung in der chip-konstruktion und chip-produktion (dna chips) |
| EP0430881A3 (en) | 1989-11-29 | 1991-10-23 | Ciba-Geigy Ag | Photochromic compounds, process for their preparation and their use |
| US5288644A (en) | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
| US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
| US5412087A (en) | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
| US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
| ATE173767T1 (de) | 1992-04-03 | 1998-12-15 | Perkin Elmer Corp | Proben zusammensetzung und verfahren |
| US5554501A (en) | 1992-10-29 | 1996-09-10 | Beckman Instruments, Inc. | Biopolymer synthesis using surface activated biaxially oriented polypropylene |
| US5503980A (en) | 1992-11-06 | 1996-04-02 | Trustees Of Boston University | Positional sequencing by hybridization |
| DE4311230C2 (de) | 1993-04-02 | 1996-12-19 | Mannesmann Ag | Nicht-spurgebundenes Fahrzeug mit Elektromotor |
| US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| US5470710A (en) | 1993-10-22 | 1995-11-28 | University Of Utah | Automated hybridization/imaging device for fluorescent multiplex DNA sequencing |
| US5472672A (en) | 1993-10-22 | 1995-12-05 | The Board Of Trustees Of The Leland Stanford Junior University | Apparatus and method for polymer synthesis using arrays |
| US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
| US5429807A (en) | 1993-10-28 | 1995-07-04 | Beckman Instruments, Inc. | Method and apparatus for creating biopolymer arrays on a solid support surface |
| US5631734A (en) | 1994-02-10 | 1997-05-20 | Affymetrix, Inc. | Method and apparatus for detection of fluorescently labeled materials |
| US5571639A (en) | 1994-05-24 | 1996-11-05 | Affymax Technologies N.V. | Computer-aided engineering system for design of sequence arrays and lithographic masks |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US5624711A (en) | 1995-04-27 | 1997-04-29 | Affymax Technologies, N.V. | Derivatization of solid supports and methods for oligomer synthesis |
| US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| US5661028A (en) | 1995-09-29 | 1997-08-26 | Lockheed Martin Energy Systems, Inc. | Large scale DNA microsequencing device |
| US6022963A (en) | 1995-12-15 | 2000-02-08 | Affymetrix, Inc. | Synthesis of oligonucleotide arrays using photocleavable protecting groups |
| DE19782096T1 (de) | 1996-11-06 | 2000-03-23 | Sequenom Inc | Immobiliserung von Nucleinsäuren in hoher Dichte |
| EP0937097B1 (en) | 1996-11-06 | 2001-08-16 | Sequenom, Inc. | Compositions and methods for immobilizing nucleic acids to solid supports |
| US6077674A (en) | 1999-10-27 | 2000-06-20 | Agilent Technologies Inc. | Method of producing oligonucleotide arrays with features of high purity |
| CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
| EP1784501B1 (en) * | 2004-05-14 | 2015-11-18 | Rosetta Genomics Ltd | VIRAL AND VIRUS ASSOCIATED MicroRNAS AND USES THEREOF |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| PL1907424T3 (pl) | 2005-07-01 | 2015-12-31 | Squibb & Sons Llc | Ludzkie monoklonalne przeciwciała wobec liganda zaprogramowanej śmierci 1 (PD-L1) |
| US8354509B2 (en) | 2007-06-18 | 2013-01-15 | Msd Oss B.V. | Antibodies to human programmed death receptor PD-1 |
| JP2011502513A (ja) * | 2007-11-09 | 2011-01-27 | ジェネンテック， インコーポレイテッド | 癌患者における診断用途のための方法および組成物 |
| JP2012500652A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | 標的化共刺激ポリペプチドおよび癌を処置するための使用方法 |
| RU2017132160A (ru) | 2008-12-09 | 2019-02-08 | Дженентек, Инк. | Антитела к pd-l1 и их применение для усиления функции t-клеток |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| US9404926B2 (en) * | 2010-01-29 | 2016-08-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Immune gene signatures in cancer |
| PL2691112T3 (pl) | 2011-03-31 | 2018-09-28 | Merck Sharp & Dohme Corp. | Stabilne preparaty przeciwciał przeciw ludzkiemu receptorowi programowanej śmierci pd-1 i terapie powiązane |
| CA2843595C (en) | 2011-08-01 | 2022-10-18 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| JP2015505300A (ja) * | 2011-11-23 | 2015-02-19 | アムジエン・インコーポレーテツド | インターフェロンγに対する抗体を使用した治療方法 |
| NO2872646T3 (enExample) | 2012-07-12 | 2018-01-27 | ||
| WO2014015006A1 (en) * | 2012-07-19 | 2014-01-23 | Tensorcom, Inc. | Method and apparatus for a 60 ghz endfire antenna |
| CA2918608A1 (en) * | 2012-08-03 | 2014-02-06 | Icahn School Of Medicine At Mount Sinai | Biomarker associated with risk of melanoma reoccurrence |
| KR102389677B1 (ko) | 2013-03-15 | 2022-04-21 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
| WO2014194293A1 (en) * | 2013-05-30 | 2014-12-04 | Amplimmune, Inc. | Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof |
| EP3084003A4 (en) | 2013-12-17 | 2017-07-19 | Merck Sharp & Dohme Corp. | Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists |
| US20160312295A1 (en) | 2013-12-17 | 2016-10-27 | Merck Sharp & Dohme Corp. | Gene signature biomarkers of tumor response to pd-1 antagonists |
| US20160312297A1 (en) | 2013-12-17 | 2016-10-27 | Merck Sharp & Dohme Corp. | Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists |
| EP3839510A3 (en) | 2015-04-17 | 2021-08-25 | Merck Sharp & Dohme Corp. | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists |
-
2015
- 2015-12-08 BR BR112017012222A patent/BR112017012222A2/pt not_active Application Discontinuation
- 2015-12-08 RU RU2017123117A patent/RU2017123117A/ru not_active Application Discontinuation
- 2015-12-08 CA CA2968406A patent/CA2968406A1/en not_active Abandoned
- 2015-12-08 CN CN201580072918.XA patent/CN107109700A/zh active Pending
- 2015-12-08 JP JP2017530266A patent/JP2018505658A/ja active Pending
- 2015-12-08 AU AU2015360736A patent/AU2015360736A1/en not_active Abandoned
- 2015-12-08 US US15/533,769 patent/US11377693B2/en active Active
- 2015-12-08 KR KR1020177018558A patent/KR20170086661A/ko not_active Withdrawn
- 2015-12-08 WO PCT/US2015/064445 patent/WO2016094377A1/en not_active Ceased
- 2015-12-08 EP EP15868101.5A patent/EP3230498B1/en active Active
- 2015-12-08 MX MX2017007535A patent/MX2017007535A/es unknown
-
2020
- 2020-07-08 AU AU2020204557A patent/AU2020204557A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018505658A5 (enExample) | ||
| Mohan et al. | Profiling of circulating free DNA using targeted and genome-wide sequencing in patients with SCLC | |
| Tian et al. | Crosstalk between 5-methylcytosine and N6-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic landscape in hepatocellular carcinoma | |
| RU2017123117A (ru) | Система и способы получения биомаркеров генных сигнатур ответа на антагонисты pd-1 | |
| Wong et al. | Poor survival with wild-type TP53 ovarian cancer? | |
| JP2017508970A5 (enExample) | ||
| Popovici et al. | Selecting control genes for RT-QPCR using public microarray data | |
| CN112908470A (zh) | 一种基于rna结合蛋白基因的肝细胞癌预后评分系统及其应用 | |
| CN113444804B (zh) | 宫颈癌预后相关基因及其在制备宫颈癌预后预测诊断产品中的应用 | |
| CN107974506A (zh) | 一种用于急性髓系白血病药物指示的方法及装置 | |
| CN106148529A (zh) | 与胃癌相关的LncRNA标记物及其专用检测引物、检测方法、试剂盒与应用 | |
| JP2016515800A5 (enExample) | ||
| JP2015047101A (ja) | 乳癌術前化学療法に対する感受性の診断補助方法および判定装置 | |
| JP2016073287A (ja) | 腫瘍特性及びマーカーセットの同定のための方法、腫瘍分類、並びに癌のマーカーセット | |
| CN117625793B (zh) | 一种卵巢癌生物标志物的筛选方法及其应用 | |
| Gu et al. | Inflammation-related LncRNAs signature for prognosis and immune response evaluation in uterine corpus endometrial carcinoma | |
| Kaur et al. | Comprehensive identification of pleiotropic loci for body fat distribution using the NHGRI‐EBI Catalog of published genome‐wide association studies | |
| CN109880905B (zh) | 一组用于三阴性乳腺癌免疫组化分型的基因及其应用 | |
| Shen et al. | Predicting the immune landscape of invasive breast carcinoma based on the novel signature of immune‐related lncRNA | |
| Laborde et al. | Transcriptional profiling by sequencing of oropharyngeal cancer | |
| CN107653312B (zh) | 与血脂水平和冠心病相关的rs7901016检测系统及相关应用 | |
| Munkácsy et al. | Gene expression-based prognostic and predictive tools in breast cancer | |
| CN108913773A (zh) | 一种临床评价卵巢癌铂类药物化疗敏感性的多分子标志物及其装置与评价方法 | |
| CN118711662A (zh) | 一种乳腺癌患者新辅助化疗敏感性的预测装置 | |
| CA2894660C (en) | Method and apparatus for detecting cancer in mammals |